Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue
Branded Legacy Inc. (OTC: BLEG) announced a major leadership transition and pending merger with an innovative addiction therapeutics company. The entire existing management team has resigned, with Jeffery Robison appointed as Interim CEO. A Letter of Intent is expected to be executed this week, with merger completion anticipated within two weeks.
The target company specializes in advanced intranasal drug delivery systems, particularly for Naloxone, featuring a patented all-in-one device that reduces costs and improves treatment consistency. Their technology platform includes a second device enabling point-of-care reconstitution of medications, expanding into vaccines and cold chain-dependent therapeutics.
The merged entity projects $40 million in first-year revenue. The global addiction treatment market is expected to grow from $9 billion in 2023 to $16.7 billion by 2033, with the naloxone market projected to reach $2.48 billion by 2032.
Branded Legacy Inc. (OTC: BLEG) ha annunciato un importante cambiamento nella leadership e una fusione imminente con una società innovativa nel campo delle terapie per la dipendenza. L'intero team di gestione attuale si è dimesso, con Jeffery Robison nominato CEO ad interim. Si prevede la firma di una Lettera di Intenti entro questa settimana, con il completamento della fusione atteso entro due settimane.
La società target è specializzata in avanzati sistemi di somministrazione intranasale di farmaci, in particolare per il Naloxone, con un dispositivo brevettato tutto-in-uno che riduce i costi e migliora la coerenza del trattamento. La loro piattaforma tecnologica include un secondo dispositivo che consente la ricostituzione dei farmaci al punto di cura, estendendo l'applicazione a vaccini e terapie che richiedono la catena del freddo.
La nuova entità risultante dalla fusione prevede 40 milioni di dollari di ricavi nel primo anno. Il mercato globale dei trattamenti per la dipendenza è stimato crescere da 9 miliardi di dollari nel 2023 a 16,7 miliardi entro il 2033, con il mercato del naloxone previsto raggiungere 2,48 miliardi di dollari entro il 2032.
Branded Legacy Inc. (OTC: BLEG) anunció una importante transición en su liderazgo y una fusión pendiente con una empresa innovadora en terapias para la adicción. Todo el equipo directivo actual ha renunciado, y Jeffery Robison ha sido nombrado CEO interino. Se espera que esta semana se firme una Carta de Intención, y la fusión se complete en un plazo de dos semanas.
La empresa objetivo se especializa en avanzados sistemas de administración intranasal de medicamentos, especialmente para Naloxona, con un dispositivo patentado todo en uno que reduce costos y mejora la consistencia del tratamiento. Su plataforma tecnológica incluye un segundo dispositivo que permite la reconstitución de medicamentos en el punto de atención, ampliando su uso a vacunas y terapias que requieren cadena de frío.
La entidad fusionada proyecta 40 millones de dólares en ingresos durante el primer año. Se espera que el mercado global de tratamientos para la adicción crezca de 9 mil millones de dólares en 2023 a 16.7 mil millones para 2033, y que el mercado de naloxona alcance 2.48 mil millones de dólares para 2032.
Branded Legacy Inc. (OTC: BLEG)는 혁신적인 중독 치료 회사와의 주요 리더십 교체 및 예정된 합병을 발표했습니다. 기존 경영진 전원이 사임했으며, Jeffery Robison이 임시 CEO로 임명되었습니다. 이번 주에 의향서가 체결될 예정이며, 합병 완료는 2주 이내로 예상됩니다.
대상 회사는 특히 날록손(Naloxone)용 고급 비강 투여 시스템을 전문으로 하며, 비용을 절감하고 치료 일관성을 향상시키는 특허받은 올인원 장치를 보유하고 있습니다. 이들의 기술 플랫폼에는 약물 현장 재구성을 가능하게 하는 두 번째 장치가 포함되어 있어 백신 및 냉장 보관이 필요한 치료제로 확장되고 있습니다.
합병된 법인은 첫 해 매출 4천만 달러를 예상합니다. 전 세계 중독 치료 시장은 2023년 90억 달러에서 2033년 167억 달러로 성장할 것으로 예상되며, 날록손 시장은 2032년까지 24억 8천만 달러에 이를 전망입니다.
Branded Legacy Inc. (OTC: BLEG) a annoncé une importante transition de direction et une fusion imminente avec une entreprise innovante spécialisée dans les thérapies contre la dépendance. Toute l'équipe de direction actuelle a démissionné, avec Jeffery Robison nommé PDG par intérim. Une lettre d'intention devrait être signée cette semaine, la fusion étant prévue dans les deux semaines.
L'entreprise cible est spécialisée dans les systèmes avancés d'administration intranasale de médicaments, notamment pour le naloxone, avec un dispositif breveté tout-en-un qui réduit les coûts et améliore la constance du traitement. Leur plateforme technologique comprend un second dispositif permettant la reconstitution des médicaments au point de soins, s'étendant aux vaccins et aux thérapeutiques nécessitant la chaîne du froid.
L'entité fusionnée prévoit 40 millions de dollars de revenus la première année. Le marché mondial du traitement de la dépendance devrait passer de 9 milliards de dollars en 2023 à 16,7 milliards d'ici 2033, avec un marché du naloxone estimé à 2,48 milliards de dollars d'ici 2032.
Branded Legacy Inc. (OTC: BLEG) gab einen bedeutenden Führungswechsel und eine bevorstehende Fusion mit einem innovativen Unternehmen für Suchttherapien bekannt. Das gesamte bestehende Managementteam ist zurückgetreten, und Jeffery Robison wurde zum Interims-CEO ernannt. Eine Absichtserklärung soll noch diese Woche unterzeichnet werden, die Fusion wird innerhalb von zwei Wochen erwartet.
Das Zielunternehmen spezialisiert sich auf fortschrittliche intranasale Arzneimittelabgabesysteme, insbesondere für Naloxon, mit einem patentierten All-in-One-Gerät, das Kosten senkt und die Behandlungskonsistenz verbessert. Ihre Technologieplattform umfasst ein zweites Gerät, das die Rekonstitution von Medikamenten am Behandlungsort ermöglicht und sich auf Impfstoffe und kältekettenabhängige Therapeutika ausweitet.
Das fusionierte Unternehmen prognostiziert 40 Millionen US-Dollar Umsatz im ersten Jahr. Der globale Markt für Suchtbehandlungen wird voraussichtlich von 9 Milliarden US-Dollar im Jahr 2023 auf 16,7 Milliarden bis 2033 wachsen, während der Naloxon-Markt bis 2032 auf 2,48 Milliarden US-Dollar geschätzt wird.
- Projected first-year revenue of $40 million from the merged entity
- Entry into high-growth addiction therapeutics market valued at $9 billion with 6.6% CAGR
- Patented all-in-one intranasal device technology reducing costs and improving treatment delivery
- Expansion potential into vaccines and cold chain-dependent medications market
- Integration of experienced management team with expertise in addiction therapeutics and medicine delivery systems
- Complete resignation of existing management team creating transitional uncertainty
- Merger completion subject to regulatory approvals and final agreements
- Significant shift in business focus from plant-based wellness to addiction therapeutics
ORLANDO, Fla., July 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy Inc. (OTC: BLEG), a diversified holdings company, today announced significant changes in its leadership structure and a strategic merger initiative aimed at positioning the company for growth in the burgeoning addiction therapeutics sector.
Effective immediately, David Oswald, Philip White, and the entire existing management team have resigned from their positions at Branded Legacy Inc. The company expresses gratitude for their contributions and wishes them success in their future endeavors.
Jeffery Robison has been appointed as Interim CEO to guide the company through this transitional period. In his role, Mr. Robison is leading negotiations for a major merger with an innovative addiction therapeutics company. A Letter of Intent (LOI) has been submitted and is expected to be executed this week, with full execution anticipated by week's end. The merger is projected to close within the next two weeks, subject to final agreements and regulatory approvals.
Addictions represent a globally increasing health crisis, with current treatments often proving ineffective, expensive, and inaccessible to many patients. The target company has developed advanced technology and assembled leading experts to address this challenge, with a focus on Naloxone, which is leading the intranasal device market for opioid overdose reversal.
The target company is revolutionizing intranasal drug delivery by redesigning naloxone administration as an all-in-one device that reduces costs while overcoming limitations of existing market products. Their patented all-in-one device simplifies what is currently a complex, multi-part system, thereby lowering operational complexity and enhancing dose precision for improved treatment consistency, simplified prescribing, and easier usage.
Beyond naloxone, the target company's innovative platform enables nasal administration of compounds that conventional intranasal devices cannot reliably deliver due to physical, chemical, or manufacturing constraints, opening up new treatment options. A second device invention allows for mixing solutions with lyophilized powder, expanding into additional markets such as vaccines and other medications that were previously inaccessible. This intranasal delivery approach facilitates quicker pandemic responses, enables self-use vaccination, and supports underserved, hard-to-reach regions globally. For many medications requiring continuous refrigeration—the "cold chain"—this point-of-care reconstitution capability significantly streamlines delivery logistics.
As part of its strategy, the target company is targeting other cold chain-dependent medications to further broaden its impact in global health solutions.
This merger will integrate a highly accomplished and reputable management team with extensive expertise in addiction therapeutics and advanced medicine delivery systems. Key members include a professor holding a PhD, renowned for expertise in health research methods, evidence synthesis, and impact, who has led groundbreaking clinical trials, including high-profile studies on drug effectiveness for COVID-19 and preventive therapeutics, contributing to global health advancements with a focus on rigorous evidence-based medicine; a biostatistician and doctor, a serial entrepreneur with over 15 years in data science and AI, who has founded multiple health technology companies leading to successful exits, specializing in innovative clinical trial designs, Bayesian statistics, meta-analysis, and complex evidence synthesis; and the President & CEO, a pharmacist and clinical research coordinator with a strong background in pharmaceutical sciences, clinical development, and coordinating research efforts to advance therapeutic solutions.
The incoming team's innovations emphasize cost-effective solutions that enhance accessibility and efficiency in treatment delivery, aligning with Branded Legacy's vision for transformative growth. The combined entity projects revenue of
"The addiction therapeutics industry represents a dynamic and rapidly expanding market, poised for substantial advancement," said Jeffery Robison, Interim CEO of Branded Legacy Inc. "According to recent industry reports, the global addiction treatment market was valued at approximately
The merger is expected to diversify Branded Legacy's portfolio, leveraging the new team's proven track record in developing therapies that address unmet needs in addiction treatment while emphasizing cost-efficiency.
Branded Legacy Inc. remains committed to transparency and will provide updates as the merger progresses. Investors and stakeholders are encouraged to monitor the company's filings for further details.
About Branded Legacy Inc.
Branded Legacy, Inc. (OTC: BLEG) is a diversified holding company focused on plant-based functional wellness and the rapidly expanding cannabis beverage sector. With a commitment to excellence and innovation, Branded Legacy specializes in the development and marketing of cutting-edge products and services, including ventures in biotechnology, digital solutions, and wellness products.
For more information, please contact:
Jeffery Robison
Branded Legacy
Phone: 877-250-9077
Email: info@brandedlegacy.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause such differences include, but are not limited to, the successful execution of the LOI, completion of the merger, regulatory approvals, and market conditions. Branded Legacy Inc. undertakes no obligation to update any forward-looking statements.
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the projected revenue for Branded Legacy (BLEG) after the merger?
Who is the new CEO of Branded Legacy (BLEG)?
What is the target market size for BLEG's addiction treatment business?
What is unique about BLEG's merger target company's technology?
When is the BLEG merger expected to close?
